• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Astrocytoma - Pipeline Review, H2 2011 - Product Image

Astrocytoma - Pipeline Review, H2 2011

  • ID: 1881595
  • August 2011
  • 152 pages
  • Global Markets Direct

Astrocytoma - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Astrocytoma - Pipeline Review, H2 2011', provides an overview of the Astrocytoma therapeutic pipeline. This report provides information on the therapeutic development for Astrocytoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Astrocytoma. 'Astrocytoma - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Astrocytoma.
- A review of the Astrocytoma products under development by companies and universities/research institutes based on information derived from company and READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Astrocytoma Overview
Therapeutics Development
An Overview of Pipeline Products for Astrocytoma
Astrocytoma Therapeutics under Development by Companies
Astrocytoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Astrocytoma Therapeutics - Products under Development by Companies
Astrocytoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Astrocytoma Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Lentigen Corporation
Sangamo BioSciences, Inc.
Takeda Pharmaceutical Company Limited
YM BioSciences Inc.
MediGene AG
Ark Therapeutics Group plc
Novartis AG
Eisai Co., Ltd.
Nippon Shinyaku Co., Ltd.
OSI Pharmaceuticals, Inc.
Pfizer Inc.
Genmab A/S
Exelixis, Inc.
Celgene Corporation
Geron Corporation
University of California, San Francisco
Merck KGaA
Access Pharmaceuticals, Inc.
EntreMed, Inc.
Celldex Therapeutics, Inc.
ImmunoCellular Therapeutics, Ltd.
Lixte Biotechnology Holdings, Inc.
Northwest Biotherapeutics, Inc.
Oncolytics Biotech Inc.
Oncothyreon Inc
Peregrine Pharmaceuticals, Inc.
Telik, Inc.
Pharmacyclics, Inc.
PhytoMedical Technologies, Inc.
Transgene SA
Sareum Holdings plc
Bradmer Pharmaceuticals Inc.
Proximagen Neuroscience plc.
Protox Therapeutics Inc.
Rexahn Pharmaceuticals, Inc.
Debiopharm Group
Antisense Pharma GmbH
INSYS Therapeutics, Inc.
Ambit Biosciences Corporation
Immupharma Plc
immatics biotechnologies GmbH
Advantagene, Inc.
Apogenix GmbH
Indena S.p.A.
Oncolin Therapeutics, Inc.
Unibioscreen S.A.
Reata Pharmaceuticals, Inc.
Vascular Biogenics Ltd.
BioCancell Therapeutics, Inc.
Axelar AB
Siena Biotech S.p.A.
Myriad Pharmaceuticals, Inc.
BiPar Sciences, Inc.
ChemoCentryx, Inc.
TVAX Biomedical, LLC
Sirnaomics, Inc.
Hy BioPharma Inc.
AVEO Pharmaceuticals, Inc.
ZGene A/S
Nexgenix Pharmaceuticals, LLC
Archer Biosciences, Inc
Direct Therapeutics, Inc.
TAU Therapeutics, LLC
Tocagen Inc
CytomX, LLC.
Astrocytoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Enzastaurin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cilengitide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IL13-PE38QQR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trabedersen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xcytrin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cerepro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cediranib + Lomustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SU-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cilengitide + Temozolomide + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec + Hydroxyurea - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin + Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lomustine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carmustine + O6-Benzylguanine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carmustine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Lomustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Procarbazine + ACNU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + ACNU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thioguanine + Procarbazine + Lomustine + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radiation therapy + carmustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Procarbazine + Lomustine + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temodal + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Astrocytoma Therapeutics – Drug Profile Updates
Astrocytoma Therapeutics - Discontinued Products
Astrocytoma - Featured News
Aug 18, 2011: Cell Therapeutics Announces Enrollment Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors
Aug 04, 2011: Northwest Biotherapeutics Announces Further Expansion Of Clincal Sites In Ongoing Brain Cancer Trial
Jul 26, 2011: Diffusion Pharmaceuticals Receives FDA Orphan Status For TSC For Treatment Of Primary Brain Cancer
Jul 08, 2011: Novartis’s Afinitor Meets Primary Endpoint Of Reducing SEGA Tumor Size In Patients With Tuberous Sclerosis In Phase III Study
Jun 23, 2011: Arno Therapeutics Reports Positive Interim Results For AR-67 in Glioblastoma Study
Jun 22, 2011: ImmunoCellular Therapeutics To Present ICT-107 At Second World Cancer Vaccines Summit
Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide’s Pivotal Phase III Trial CENTRIC
Jun 09, 2011: ImmunoCellular Therapeutics Expands Phase II Trial Of ICT-107
Jun 07, 2011: Tocagen's First-in-Human Clinical Trial Of Toca 511 Enrolling Patients With High Grade Glioma
Jun 06, 2011: Myrexis Reports Azixa Phase II Study Results At 2011 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Astrocytoma, H2 2011
Products under Development for Astrocytoma – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, 2011
Boehringer Ingelheim GmbH, 2011
F. Hoffmann-La Roche Ltd., 2011
Amgen Inc., 2011
Sanofi-Aventis, 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
Daiichi Sankyo Company, Ltd, 2011
Merck & Co., Inc., 2011
Lentigen Corporation, 2011
Sangamo BioSciences, Inc., 2011
Takeda Pharmaceutical Company Limited, 2011
YM BioSciences Inc., 2011
MediGene AG, 2011
Ark Therapeutics Group plc, 2011
Novartis AG, 2011
Eisai Co., Ltd., 2011
Nippon Shinyaku Co., Ltd., 2011
OSI Pharmaceuticals, Inc., 2011
Pfizer Inc., 2011
Genmab A/S, 2011
Exelixis, Inc., 2011
Celgene Corporation, 2011
Geron Corporation, 2011
University of California, San Francisco, 2011
Merck KGaA, 2011
Access Pharmaceuticals, Inc., 2011
EntreMed, Inc., 2011
Celldex Therapeutics, Inc., 2011
ImmunoCellular Therapeutics, Ltd., 2011
Lixte Biotechnology Holdings, Inc., 2011
Northwest Biotherapeutics, Inc., 2011
Oncolytics Biotech Inc., 2011
Oncothyreon Inc, 2011
Peregrine Pharmaceuticals, Inc., 2011
Telik, Inc., 2011
Pharmacyclics, Inc., 2011
PhytoMedical Technologies, Inc., 2011
Transgene SA, 2011
Sareum Holdings plc, 2011
Bradmer Pharmaceuticals Inc., 2011
Proximagen Neuroscience plc., 2011
Protox Therapeutics Inc., 2011
Rexahn Pharmaceuticals, Inc., 2011
Debiopharm Group, 2011
Antisense Pharma GmbH, 2011
INSYS Therapeutics, Inc., 2011
Ambit Biosciences Corporation, 2011
Immupharma Plc, 2011
immatics biotechnologies GmbH, 2011
Advantagene, Inc., 2011
Apogenix GmbH, 2011
Indena S.p.A., 2011
Oncolin Therapeutics, Inc., 2011
Unibioscreen S.A., 2011
Reata Pharmaceuticals, Inc., 2011
Vascular Biogenics Ltd., 2011
BioCancell Therapeutics, Inc., 2011
Axelar AB, 2011
Siena Biotech S.p.A., 2011
Myriad Pharmaceuticals, Inc., 2011
BiPar Sciences, Inc., 2011
ChemoCentryx, Inc., 2011
TVAX Biomedical, LLC, 2011
Sirnaomics, Inc., 2011
Hy BioPharma Inc., 2011
AVEO Pharmaceuticals, Inc., 2011
ZGene A/S, 2011
Nexgenix Pharmaceuticals, LLC, 2011
Archer Biosciences, Inc, 2011
Direct Therapeutics, Inc., 2011
TAU Therapeutics, LLC, 2011
Tocagen Inc, 2011
CytomX, LLC., 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Astrocytoma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Astrocytoma, H2 2011
Products under Development for Astrocytoma – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos